hotspot -WSS

hotspot

author：hotspot 2025-09-27 21:07:45 - browse：67363

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Amazon on where the company's health care bets are headed next

hotspot

WSS

UnitedHealth financials solid despite Change Healthcare cyberattack

What drug price negotiations mean for Medicare Part D

More tobacco lobbyists active in statehouses

Getting Alzheimer's drug Leqembi to patients can be a challenge

Crinetics acromegaly drug succeeds in late

Stem cell treatment guidelines are released by FDA

explore

hotspot

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

H5N1 bird flu found in pasteurized milk: what we know

Peter Hotez and the public health issue of online harassment

Melinda French Gates resigns from Gates Foundation

Wildfire smoke exposes gaps in outdoor worker protections

Q&A: Jennifer Adair on making gene therapy available globally

Affirmative action in medical school literally saved lives

More tobacco lobbyists active in statehouses

Alkermes shareholders re

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

hotspot

More tobacco lobbyists active in statehouses

Exact Sciences stock tumbles despite strong cancer detection sales

Melinda French Gates resigns from Gates Foundation

AstraZeneca chief proposes a novel edit to the drug pricing bill

More tobacco lobbyists active in statehouses

How to protect patients from sexual assault

Wikipedia

hotspot

focus

hotspot